Skip to main content

Table 4 Drug Exposure

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

 

Cilengitide + Gemcitabine n = 44

Gemcitabine n = 42

 

Cilengitide

Gemcitabine

Gemcitabine

Mean duration ± SD, days

134 ± 89

120 ± 75

Median duration (range), days

133 (1–344)

135 (1–330)

Mean no. cycles ± SD

4.8 ± 4.0

4.1 ± 2.7

Median no. cycles (range)

4.5 (0–19)

4.5 (1–12)

Mean RDI ± SD 1st 6 mths (range), %

93 ± 11

94 ± 11

89 ± 15

Median RDI 1st 6 mths (range), %

97 (53–101)

99 (55–104)

96 (47–105)

  1. Abbreviations: SD, standard deviation; RDI, relative dose intensity; mths, months.
  2. RDI = % of planned total dosage
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us